Literature DB >> 25187314

Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia.

Nikolay N Klimko1, Sofya N Khostelidi, Alisya G Volkova, Marina O Popova, Tatyana S Bogomolova, Ludmila S Zuborovskaya, Aleksey S Kolbin, Nadezhda V Medvedeva, Ilya S Zuzgin, Sergey M Simkin, Nataliya V Vasilyeva, Boris V Afanasiev.   

Abstract

We prospectively observed 36 haematological patients with mucormycosis from nine hospitals of St. Petersburg during 2004-2013. The most frequent underlying diseases were acute leukaemia (64%), and main risk factors were prolonged neutropenia (92%) and lymphocytopenia (86%). In 50% of the patients, mucormycosis was diagnosed 1-65 days after invasive aspergillosis. Main clinical form of mucormycosis was pulmonary (64%), while two or more organ involvement was noted in 50% of the cases. The most frequent aetiological agents of mucormycosis were Rhizopus spp. (48%). Twelve-week survival rate was 50%. Combination therapy (echinocandins + amphotericin B forms) and recovery from the underlying disease significantly improved the survival rate.
© 2014 Blackwell Verlag GmbH.

Entities:  

Keywords:  Lichtheimia corymbifera; Mucormycosis; acute leukaemia; haematological malignancy; mucormycosis; pulmonary mucormycosis; skin and soft tissue

Mesh:

Substances:

Year:  2014        PMID: 25187314     DOI: 10.1111/myc.12247

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

Review 1.  Combined Orofacial Aspergillosis and Mucormycosis: Fatal Complication of a Recurrent Paediatric Glioma-Case Report and Review of Literature.

Authors:  Maddalena Chermetz; Margherita Gobbo; Katia Rupel; Giulia Ottaviani; Giancarlo Tirelli; Rossana Bussani; Roberto Luzzati; Roberto Di Lenarda; Matteo Biasotto
Journal:  Mycopathologia       Date:  2016-06-27       Impact factor: 2.574

Review 2.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 3.  Challenges in the diagnosis and treatment of mucormycosis.

Authors:  A Skiada; C Lass-Floerl; N Klimko; A Ibrahim; E Roilides; G Petrikkos
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

4.  COVID-19 Associated Mucormycosis with Newly Diagnosed Diabetes Mellitus in Young Males - A Tertiary Care Experience.

Authors:  Sahil Kapoor; Poonam Kumar Saidha; Ayushi Gupta; Urvi Saini; Sneha Satya
Journal:  Int Arch Otorhinolaryngol       Date:  2022-07-14

5.  The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis.

Authors:  Kazem Ahmadikia; Seyed Jamal Hashemi; Sadegh Khodavaisy; Muhammad Ibrahim Getso; Neda Alijani; Hamid Badali; Hossein Mirhendi; Mohammadreza Salehi; Azin Tabari; Mojtaba Mohammadi Ardehali; Mohammad Kord; Emmanuel Roilides; Sassan Rezaie
Journal:  Mycoses       Date:  2021-03-05       Impact factor: 4.931

Review 6.  Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.

Authors:  Rohit Sharma; Praveen Kumar; Abdur Rauf; Ashun Chaudhary; Pradeep Kumar Prajapati; Talha Bin Emran; Clara Mariana Gonçalves Lima; Carlos Adam Conte-Junior
Journal:  Front Cell Infect Microbiol       Date:  2022-07-18       Impact factor: 6.073

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.